Skip to main content
Log in

Tracleer Tackling Pulmonary Fibrosis

Endothelin Blocker Close to Market

  • Emerging Technology
  • Published:
Pharmaceutical & Diagnostic Innovation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I

Notes

  1. Bosentan Use in Interstitial Lung Diseases.

  2. International Study of Survival Outcomes in Idiopathic Pulmonary Fibrosis With Interferon Gamma Early Intervention.

References

  1. European Biotechnology. Actelion. Tracleer clinician call review. New York: Lehman Brothers Equity Research 2005

    Google Scholar 

  2. European Biotechnology. Actelion. No change to numbers following R&D day. New York: Lehman Brothers Equity Research 2005

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tracleer Tackling Pulmonary Fibrosis. Pharmaceutical & Diagnostic Innovation 3, 8–12 (2005). https://doi.org/10.1007/BF03256992

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256992

Keywords

Navigation